Quiz|Articles|January 31, 2025

How Well Do You Know the January 2025 Issue of AJMC?

Test your knowledge of the first issue of AJMC's anniversary year!

True or False: Increased use of mental health services was associated with network adequacy standards.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

ByMaggie L. Shaw,Kerry Rogers, MD

July 11th 2026

4 Dice that spell out "FDA Approved" surrounded by pills on a table. | Image Credit: Frank H.-stock.adobe.com.jpeg

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

ByElla Hohmann, MS

July 10th 2026

Parasite | Image credit: @ecrow_AdobeStock.jpeg

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

BySabrina McCrear

July 10th 2026

AI text with icons floating above it. | Image Credit: Zenzeta-stock.adobe.com.jpeg

AI Chatbots Score Below 28% on Colorectal Cancer Questions

ByElla Hohmann, MS

July 10th 2026

Woman stands on the scales. Measuring tape. Weight loss - Atlas - stock.adobe.com

Setmelanotide Cuts BMI, Hunger in Phase 3 Trial for Hypothalamic Obesity

ByGiuliana Grossi

July 10th 2026

How Well Do You Know the January 2025 Issue of AJMC?

Related Content

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

AI Chatbots Score Below 28% on Colorectal Cancer Questions

Setmelanotide Cuts BMI, Hunger in Phase 3 Trial for Hypothalamic Obesity

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Health Equity & Access Weekly Roundup: July 10, 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

How Well Do You Know the January 2025 Issue of AJMC?

Related Content

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

AI Chatbots Score Below 28% on Colorectal Cancer Questions

Setmelanotide Cuts BMI, Hunger in Phase 3 Trial for Hypothalamic Obesity

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Health Equity & Access Weekly Roundup: July 10, 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma